Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.

@article{Bristow2004EffectOB,
  title={Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.},
  author={Michael R. Bristow and Heidi J Krause-Steinrauf and Rebecca Nuzzo and Cheng-Seng Liang and Jo Ann Lindenfeld and Brian D. Lowes and Brack G. Hattler and William T. Abraham and Lisa A Olson and Steven D. Krueger and Surai Thaneemit-Chen and Joshua M Hare and Henry S. Loeb and Michael J. Domanski and Eric J. Eichhorn and Robert Zelis and Phil Lavori},
  journal={Circulation},
  year={2004},
  volume={110 11},
  pages={1437-42}
}
BACKGROUND Adrenergic activation is thought to be an important determinant of outcome in subjects with chronic heart failure (CHF), but baseline or serial changes in adrenergic activity have not been previously investigated in a large patient sample treated with a powerful antiadrenergic agent. METHODS AND RESULTS Systemic venous norepinephrine was measured at baseline, 3 months, and 12 months in the beta-Blocker Evaluation of Survival Trial (BEST), which compared placebo treatment with the… CONTINUE READING
34 Citations
19 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

The effect of diabetes on outcome of advanced heart failure patients in the BEST Trial

  • M Domanski, H Krause-Steinrauf, P Deedwania
  • J Am Coll Cardiol
  • 2003

The effects of moxonidine SR, an imidazoline agonist, on plasma norepinephrine in patients with congestive heart failure

  • K Swedberg, MR Bristow, JN Cohn
  • Circulation
  • 2002

A trial of the beta-adrenergic blocker bucindolol in patients with advanced heart failure

  • BEST Trial Investigators
  • N Engl J Med
  • 2001

Similar Papers

Loading similar papers…